(MENAFN- GlobeNewsWire - Nasdaq) PITTSBURGH, Nov. 23, 2022 (GLOBE NEWSWIRE) -- krystal biotech, inc. (the“Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the Evercore ISI 5th Annual HealthCONx Conference, which is taking place virtually from November 29-December 1.
Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat during the conference and host investor meetings on November 30.
A webcast of the presentation will be available here at 10:30 am ET on Wednesday, November 30 and will be posted on the Investor section of the Company's website .
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The Company's wide-ranging pipeline is based on its proprietary redosable HSV vector. Headquartered in Pittsburgh, Pennsylvania, the Company is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization. For more information, please visit , and follow @KrystalBiotech on linkedin and twitter .
CONTACT:
Investors and Media
Meg Dodge
Krystal Biotech
Source: Krystal Biotech, Inc.
MENAFN23112022004107003653ID1105224406
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.